Management of Residual Lung Disease After 3 Cycles of BEP for Nonseminoma

Immediate Assessment and Surgical Intervention

The European Society for Medical Oncology recommends surgical resection of all residual pulmonary masses >1 cm, provided tumor markers have normalized or are declining 1, 2, 3, 4
Tumor marker status should be assessed by measuring AFP, β-HCG, and LDH to confirm normalization or continued decline 3, 5, 4
The size of residual masses should be evaluated, and any lesion >1 cm diameter requires resection 1, 2, 3
Restaging should occur 4 weeks after the last chemotherapy cycle 3, 5

The American Society of Clinical Oncology states that residual masses after chemotherapy in nonseminoma frequently contain either viable malignant germ cell tumor (10%) or mature teratoma (40%), both of which require surgical excision 4
Surgical resection is mandatory regardless of marker status, as teratoma is chemotherapy-resistant and can undergo malignant transformation, and viable tumor indicates incomplete response 4

The National Comprehensive Cancer Network recommends that all sites of residual pulmonary disease must be resected, even if retroperitoneal disease was previously removed 4
The surgery should be performed by experienced thoracic/oncologic surgeons 4

If markers are normal or declining, proceed directly to surgical resection of all residual masses >1 cm 1, 2, 3, 4
If markers are rising or plateauing, do not proceed to surgery, and consider salvage chemotherapy 3, 5, 4

The European Society for Medical Oncology recommends that the next steps depend entirely on surgical pathology 1, 2, 3, 5
If necrosis/fibrosis is present, no additional chemotherapy is needed, and routine surveillance can be initiated 1, 2, 4
If mature teratoma is present, no additional chemotherapy is needed, and routine surveillance can be initiated 1, 2, 4
If viable malignant germ cell tumor is present, consolidation chemotherapy with 2 cycles of VIP (etoposide, ifosfamide, cisplatin) is recommended 2, 3, 5

Never assume that normal markers after chemotherapy mean no viable disease is present, as approximately 10% of residual masses contain viable cancer even with normalized markers 4
Avoid delaying surgery if markers are stable or declining, as delayed surgery may be more extensive with worse outcomes 4